Zealand Pharma ends recruitment for phase III study of glepaglutide
A sufficient number of patients have been enrolled for Zealand Pharma's phase III trial with glepaglutide, which is a potential treatment of short bowel syndrome (SBS).
by marketwire, translated by daniel pedersen
All of the necessary patients have been found and recruited for a phase III study of glepaglutide, which is a potential treatment of short bowel syndrome (SBS), Zealand Pharma announces in a press release on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma enters USD 200m financing agreement
For subscribers
Zealand Pharma reports positive data from phase Ib trial
For subscribers
.jpg&w=384&q=75)
